Pasithea Therapeutics (KTTA) EBITDA Margin (2022)

Pasithea Therapeutics (KTTA) posted EBITDA Margin of 2110.77% for Q4 2022, down 8.55% sequentially from 1944.49% in Q3 2022.

Pasithea Therapeutics (KTTA) EBITDA Margin (2022) Analysis & Trends

Pasithea Therapeutics has reported EBITDA Margin for 1 years, with the latest figure at 2110.77% in Q4 2022.

Quarterly EBITDA Margin changed N/A year-over-year to 2110.77% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 3134.08% (changed N/A YoY) and the FY2022 annual result came in at 3045.12%, up 2688060.0% from the prior year.
EBITDA Margin retreated to 2110.77% in Q4 2022 per KTTA's latest filing, from 1944.49% in the prior quarter.
Over five years, EBITDA Margin peaked at 1944.49% in Q3 2022 and troughed at 25866.48% in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.15%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	32.54%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	17.93%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-0.36%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	19.75%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-35.57%
10	Pasithea Therapeutics	15.13 Mn	15.13 Mn	-	-

Download Data